Lupus Science & Medicine

Papers
(The H4-Index of Lupus Science & Medicine is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort224
Genetic load in incomplete lupus erythematosus62
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children50
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol49
Towards a minimal core dataset for systemic lupus erythematosus studies46
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases44
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms42
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field39
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus37
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus37
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE32
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine29
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease29
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus28
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort26
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort25
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus24
Mesenchymal stem cells improve ovarian function by suppressing fibrosis through CTGF/FAK signalling in systemic lupus erythematosus23
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance23
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory22
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit22
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials21
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial21
0.074388027191162